A recent upgrade from H.C. Wainwright’s analyst Joseph Pantginis significantly impacted Shattuck Labs (NASDAQ: STTK), boosting its stock price by nearly 74% in December 2025. Pantginis changed his recommendation from neutral to buy and set a price target of $6 per share, which was nearly three times the stock’s previous level. This positive outlook reflects confidence in the clinical-stage biotech’s future performance.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
